TetraLogic Pharmaceuticals Corporation Announces Director Appointment

NEW YORK, NY – 1/17/2017 (PRESS RELEASE JET) — TetraLogic Pharmaceuticals Corporation (“TetraLogic” or “Company”) today announced the appointment of Mr. Alexandre Zyngier to its Board of Directors and to its management.   The appointment to the Board was effective on December 30, 2016, and, as of December 31, 2016 Mr. Zyngier is the sole director and officer of the Company.

Mr. Zyngier is a Managing Director and founder of Batuta Advisors, firm that pursues investment and advisory opportunities in the distressed and turnaround sectors. Mr. Zyngier has over 20 years of investment, strategy, and operating experience. He currently serves on the boards of directors of Atari SA, AudioEye Inc. (AEYE), GT Advanced Technologies Inc. and Torchlight Energy Resources, Inc (TRCH). Hewas previously Chairman of the Board of Vertis Inc., a director of Island One LLC and Executive Chairman of DTV America Corporation. Mr. Zyngier has worked as a Portfolio Manager, investing in public and private opportunities, at Alden Global Capital, Goldman Sachs & Co., Deutsche Bank Co. and as a sell-side distressed and event-driven analyst at CRT Capital Group. He was also a strategy consultant at McKinsey & Company. Prior to that, he was a technical brand manager at Procter & Gamble, focused on Latin America Beauty Care Products.  

On December 29, 2016, TetraLogic announced completion of the sale to Medivir AB (Nasdaq Stockholm: MVIR-B) (“Medivir”) of its SMAC mimetic program, including their clinical stage asset birinapant, and topical HDAC inhibitor, remetinostat (SHAPE).

The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Forward-Looking Statements

Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent and belief or current expectations of TetraLogic and its management team. Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016, for information regarding risk factors that could affect TetraLogic’s results. The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.

CONTACT: ir@tetralogicpharma.com

Full News Story: http://pressreleasejet.com/news/tetralogic-pharmaceuticals-corporation-announces-director-appointment.html

Distributed by Press Release Jet

Media Contact
Company Name: TetraLogic Pharmaceuticals Corporation
Contact Person: Media Relations
Email: IR@tetralogicpharma.com
Country: United States
Website: http://tetralogicpharma.com/